Boiron SA
Company Profile
Business description
Boiron SA is a drug manufacturer that focuses on homeopathic products. The company's revenue is roughly split between its nonproprietary homeopathic medicines and products in its over-the-counter specialties category. Boiron's nonproprietary medicines are generic products that do not refer to any therapeutic indication, while the specialties category includes first-resort products provided in tablet form, are bottled to use as drops, syrups, or ointments. Geographical segments are France, Europe, North America, and other countries. It generates a majority of revenue from France. The company’s products include Oscillococcinum, Stodal and Stodaline, Arnigel, Camilia, Sedatif PC, Coryzalia, Homeoptic, and Homeovox.
Contact
2, Avenue de l’Ouest Lyonnais No. 039
Messimy69510
FRAT: +33 478456100
E: finances@boiron.fr
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
2,788
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,526.90 | 320.70 | -4.09% |
| CAC 40 | 7,274.95 | 324.03 | -4.26% |
| DAX 40 | 20,641.72 | 1,075.67 | -4.95% |
| Dow JONES (US) | 38,314.86 | 2,231.07 | -5.50% |
| FTSE 100 | 8,054.98 | 419.76 | -4.95% |
| HKSE | 20,009.55 | 2,840.26 | -12.43% |
| NASDAQ | 15,587.79 | 962.82 | -5.82% |
| Nikkei 225 | 31,588.79 | 2,191.79 | -6.49% |
| NZX 50 Index | 11,775.88 | 449.40 | -3.68% |
| S&P 500 | 5,074.08 | 322.44 | -5.97% |
| S&P/ASX 200 | 7,347.40 | 320.40 | -4.18% |
| SSE Composite Index | 3,076.80 | 265.21 | -7.94% |